Teva Pharmaceuticals Axes Phase 2 Asthma Trial
Teva Pharmaceuticals has halted a phase 2 trial of TEV-48574, an investigational biologic drug for asthma patients, after interim results indicated that the treatment is unlikely to provide a significant benefit.
The study, which enrolled 65 asthma patients who were randomized to receive either TEV-48574 or placebo, failed to meet the benefit criteria based on several clinical measures, the company said.
The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).
The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.
Despite the halting of the asthma trial, TEV-48574 is in an ongoing phase 2 study for the treatment of inflammatory bowel disease.
March 25, 2022
